CheckMate 025 — Nivolumab Versus Everolimus in Previously Treated Advanced Renal Cell Carcinoma

Phase 3 · 2015 · Renal Cell Carcinoma

Design

Randomized nivolumab monotherapy vs everolimus after prior antiangiogenic therapy.

Population

Advanced clear-cell RCC previously treated with one or two antiangiogenic regimens.

Primary Endpoint

overall survival (OS)

Key Result

OS 25.0 vs 19.6 mo (HR 0.73) with fewer high-grade toxicities than everolimus.

Guideline Impact

NCCN category 1 second-line nivolumab for advanced clear-cell RCC